EU-OPENSCREEN-DRIVE Newsletter No 02 - April 2021
 
EU-OPENSCREEN-DRIVE - April 2021

Chemoproteomics and Mass Spectrometry Imaging Call 2021 (open until May 17th 2021, 16:00 CET, funded)

EU-OPENSCREEN-DRIVE offers trans-national access to target-based and phenotype-based workflows, proteomics and related advanced mass spectrometry-based technologies, with a focus on Mass Spectrometry Imaging (MSI). Our chemistry sites collaborate with partners that have a proven track-record in probe development, target deconvolution and MSI.

The project will support at least 3 successful applicants, providing target identification and compound disposition studies. Users from institutions within European member states and associated countries, and up to one user from a non-EU country, can apply for access to seven advanced proteomics and MSI facilities across Europe.

The complete call text is available at:
https://drive.eu-openscreen.eu/drive-startseite/calls/chemoproteomics-and-msi-call-2021.html.

Call overview


EU-OPENSCREEN-DRIVE chemoproteomics and MSI open call pipeline offers:

  • Mass Spectrometry Imaging (MSI) for compound disposition studies.
  • Access to appropriate in-vitro and in-vivo models and samples to support tissue disposition type studies for Mass Spectrometry Imaging applications.
  • Affinity-based target identification including synthesis of chemical probes, affinity purification and proteomics analysis.
  • Other advanced target ID methods based on cellular thermal shift assays (CETSA) and iso-thermal dose response (ITDR) experiments.
  • Standard proteomics methods including the quantitative analysis of proteins and their post-translational modifications by using label-free and label-based quantification strategies.
  • Data processing and bioinformatics data interpretation pipelines including statistical analysis.
 

Applicants will be asked to provide a detailed description of the objectives of their project, and to fulfil specific pre-requisites such as

  1. confirmed compound cellular or organismal activity in the low µM range;
  2. ideally (but not mandatory) preliminary Structure Activity Relationships (SAR) identified;
  3. ideally (but not mandatory) having an SAR-informed synthesis of linker derivatives for functional immobilization in place;
  4. ideally (but not mandatory) having an inactive compound from the same series available,
  5. ideally, for MSI studies, having a well-characterised pharmacokinetic profile (e.g. half-life, bioavailability, maximum tolerated dose, dosing route, initial formulation) and
  6. granted access to relevant biological material. All project pre-requisites for application can be found below.


Deadline for proposal submissions:
May 17th, 2021, 16:00 (CET)

For specific questions please contact:
drive@eu-openscreen.eu or help-desk-open-call@eu-openscreen.eu
 

Detailed Information


Overview: https://drive.eu-openscreen.eu/drive-startseite/calls/chemoproteomics-and-msi-call-2021.html

Involved scientific partners: https://drive.eu-openscreen.eu/drive-startseite/calls/chemoproteomics-and-msi-call-2021.html#c2240

Application requirements and submission details: https://drive.eu-openscreen.eu/drive-startseite/calls/chemoproteomics-and-msi-call-2021.html#c2239

Proposal guidelines: https://drive.eu-openscreen.eu/fileadmin/user_upload/EU-OPENSCREEN-DRIVE_Chemoprot_MSI_call2021_ProposalGuidelines_1.0.pdf

General enquiries

Phone: +49 (0)30 9489 2422
Email:  drive(at)eu-openscreen.eu
Web:   www.eu-openscreen.eu


EU-OPENSCREEN ERIC
Robert-Rössle-Str. 10, Building C87
13125 Berlin, Germany
 

Please do not forget to follow our regular up-dates on:

LinkedIn
Twitter
Facebook
Instagram

Copyright © 2021 EU-OPENSCREEN ERIC, All rights reserved.



European project funding



This project receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823893.




This newsletter was sent to you because of your former interest in EU-OPENSCREEN.
In case you are not interested in receiving further information on EU-OPENSCREEN, please use the unsubscribe button below.
 
unsubscribe from this list
 
Update subscription preferences